Somnomed Limited · ASX:SOM
Somnomed — Investor Presentation (November 2014)
7 slides from Somnomed's investor presentation, Nov 10, 2014
Slide 1: ASX Investor Presentation
For personal use only ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright ® and registered trademark notice ASX Investor Presentation | Page 0
Slide 2: Who we are
Who we are For personal use only SomnoMed Limited is the global leader in COAT™ – Continuous Open Airway Therapy; we are a globally-focused, high-growth, developer, manufacturer and marketer of oral appliances treating sleep-disordered breathing – a clinically proven, more patient friendly and cost
Slide 3: Selected financial snapshot – ASX SOM
Selected financial snapshot – ASX SOM For personal use only Market cap $124 million Sector Healthcare 52 week high / low $2.73 / $1.08 Listing date August 2004 Shares on issue 50.5 million FY14 revenue $26 million Cash balance $10 million Top-20 holders 68.4 % 5-year share price performance $2.50 $2
Slide 4: Obstructive Sleep Apnea
Obstructive Sleep Apnea For personal use only • The most common of several sleep Current treatments: disordered breathing conditions 1. Surgery • Obstructive Sleep Apnea is a collapse of the Difficult and painful upper airway which leads to a blockage of 2. Continuous Positive the airways and interr
Slide 5: Foundations for success
Foundations for success For personal use only SomnoDent devices are oral sleep apnea appliances available in multiple variations, which are customised to fit; worn at night to bring and hold lower jaw forward and keep the airways open all night. Key product • Design, proprietary materials and precis
Slide 6: Positioned for long-term growth
Positioned for long-term growth For personal use only 11. Demand growing globally 22. Broadening our product line 33. Entry into new markets APAC Sales revenue Product sales Europe $ millions Number of units USA 5 year CAGR 39% 5 year CAGR 36% 43,438 25,924 35,841 18,489 30,887 15,246 25,119 12,335
Slide 7: Positive outlook
Positive outlook For personal use only • Commercially focused, high-growth, global medical device business based in Australia • Annual growth rates of 20% to 30% will continue with evidence of acceleration • Reimbursement and insurance support are growing globally • High Gross Margin, financially st